vs
STANDARD BIOTOOLS INC.（LAB）与沃特世（WAT）财务数据对比。点击上方公司名可切换其他公司
沃特世的季度营收约是STANDARD BIOTOOLS INC.的289.4倍（$932.4M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs 24.2%，领先574.3%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 6.8%）。过去两年沃特世的营收复合增速更高（21.0% vs -73.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
沃特世是总部位于美国马萨诸塞州米尔福德的企业，面向生命科学、材料、食品等行业，提供色谱、质谱、实验室信息学、流变测量领域所用的分析仪器及配套软件，为各领域的检测、研发等工作提供可靠技术支持。
LAB vs WAT — 直观对比
营收规模更大
WAT
是对方的289.4倍
$3.2M
营收增速更快
LAB
高出255.2%
6.8%
净利率更高
LAB
高出574.3%
24.2%
两年增速更快
WAT
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $932.4M |
| 净利润 | $19.3M | $225.2M |
| 毛利率 | 83.5% | 61.1% |
| 营业利润率 | -578.6% | 29.0% |
| 净利率 | 598.5% | 24.2% |
| 营收同比 | 262.0% | 6.8% |
| 净利润同比 | 156.6% | -2.7% |
| 每股收益（稀释后） | $0.05 | $3.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABWAT
| Q4 25 | $3.2M | $932.4M | ||
| Q3 25 | $19.6M | $799.9M | ||
| Q2 25 | $21.8M | $771.3M | ||
| Q1 25 | $40.8M | $661.7M | ||
| Q4 24 | $890.0K | $872.7M | ||
| Q3 24 | $22.1M | $740.3M | ||
| Q2 24 | $22.5M | $708.5M | ||
| Q1 24 | $45.5M | $636.8M |
净利润LABWAT
| Q4 25 | $19.3M | $225.2M | ||
| Q3 25 | $-34.7M | $148.9M | ||
| Q2 25 | $-33.5M | $147.1M | ||
| Q1 25 | $-26.0M | $121.4M | ||
| Q4 24 | $-34.1M | $231.4M | ||
| Q3 24 | $-26.9M | $161.5M | ||
| Q2 24 | $-45.7M | $142.7M | ||
| Q1 24 | $-32.2M | $102.2M |
毛利率LABWAT
| Q4 25 | 83.5% | 61.1% | ||
| Q3 25 | 48.5% | 59.0% | ||
| Q2 25 | 48.8% | 58.3% | ||
| Q1 25 | 48.4% | 58.2% | ||
| Q4 24 | -202.8% | 60.1% | ||
| Q3 24 | 54.9% | 59.3% | ||
| Q2 24 | 46.1% | 59.3% | ||
| Q1 24 | 53.1% | 58.9% |
营业利润率LABWAT
| Q4 25 | -578.6% | 29.0% | ||
| Q3 25 | -168.5% | 24.0% | ||
| Q2 25 | -118.1% | 24.4% | ||
| Q1 25 | -80.8% | 22.9% | ||
| Q4 24 | -1162.1% | 33.5% | ||
| Q3 24 | -120.9% | 28.5% | ||
| Q2 24 | -134.5% | 26.7% | ||
| Q1 24 | -132.2% | 21.0% |
净利率LABWAT
| Q4 25 | 598.5% | 24.2% | ||
| Q3 25 | -177.4% | 18.6% | ||
| Q2 25 | -153.7% | 19.1% | ||
| Q1 25 | -63.8% | 18.3% | ||
| Q4 24 | -3828.3% | 26.5% | ||
| Q3 24 | -122.0% | 21.8% | ||
| Q2 24 | -203.3% | 20.1% | ||
| Q1 24 | -70.6% | 16.0% |
每股收益（稀释后）LABWAT
| Q4 25 | $0.05 | $3.76 | ||
| Q3 25 | $-0.09 | $2.50 | ||
| Q2 25 | $-0.09 | $2.47 | ||
| Q1 25 | $-0.07 | $2.03 | ||
| Q4 24 | $-0.06 | $3.88 | ||
| Q3 24 | $-0.07 | $2.71 | ||
| Q2 24 | $-0.12 | $2.40 | ||
| Q1 24 | $-0.27 | $1.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.9M | $587.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $424.3M | $2.6B |
| 总资产 | $567.8M | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.55× |
8季度趋势，按日历期对齐
现金及短期投资LABWAT
| Q4 25 | $120.9M | $587.8M | ||
| Q3 25 | $129.4M | $459.1M | ||
| Q2 25 | $158.6M | $367.2M | ||
| Q1 25 | $150.9M | $382.9M | ||
| Q4 24 | $166.7M | $325.4M | ||
| Q3 24 | $210.6M | $331.5M | ||
| Q2 24 | $269.8M | $327.4M | ||
| Q1 24 | $287.1M | $338.2M |
总债务LABWAT
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $299.0K | $1.6B | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABWAT
| Q4 25 | $424.3M | $2.6B | ||
| Q3 25 | $399.7M | $2.3B | ||
| Q2 25 | $424.5M | $2.2B | ||
| Q1 25 | $454.6M | $2.0B | ||
| Q4 24 | $471.7M | $1.8B | ||
| Q3 24 | $489.3M | $1.6B | ||
| Q2 24 | $510.3M | $1.4B | ||
| Q1 24 | $577.3M | $1.3B |
总资产LABWAT
| Q4 25 | $567.8M | $5.1B | ||
| Q3 25 | $539.6M | $4.9B | ||
| Q2 25 | $557.0M | $4.7B | ||
| Q1 25 | $579.6M | $4.6B | ||
| Q4 24 | $612.3M | $4.6B | ||
| Q3 24 | $681.5M | $4.5B | ||
| Q2 24 | $708.7M | $4.4B | ||
| Q1 24 | $777.7M | $4.5B |
负债/权益比LABWAT
| Q4 25 | — | 0.55× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | 0.89× | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $164.6M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | — |
| 自由现金流率自由现金流/营收 | -51.7% | — |
| 资本支出强度资本支出/营收 | 14.8% | — |
| 现金转化率经营现金流/净利润 | -0.06× | 0.73× |
| 过去12个月自由现金流最近4个季度 | $-82.6M | — |
8季度趋势，按日历期对齐
经营现金流LABWAT
| Q4 25 | $-1.2M | $164.6M | ||
| Q3 25 | $-22.2M | $187.3M | ||
| Q2 25 | $-20.7M | $41.1M | ||
| Q1 25 | $-30.3M | $259.6M | ||
| Q4 24 | $-14.1M | $240.1M | ||
| Q3 24 | $-27.9M | $204.6M | ||
| Q2 24 | $-39.0M | $54.5M | ||
| Q1 24 | $-62.5M | $262.9M |
自由现金流LABWAT
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | $-17.4M | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABWAT
| Q4 25 | -51.7% | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | -1959.7% | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABWAT
| Q4 25 | 14.8% | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | 380.0% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
现金转化率LABWAT
| Q4 25 | -0.06× | 0.73× | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 2.14× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 2.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
